Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 7Ipilimumab 5Nivolumab 4fludarabine 3Radiosurgery 3Drug Therapy 3Cyclophosphamide 3spartalizumab 2aldesleukin 2Sirolimus 2Riluzole 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oncolytic Virotherapy 2Counseling 2Bupropion 2Blood Specimen Collection 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tocilizumab 1sargramostim 1saracatinib 1pertuzumab 1pazopanib 1liposomal doxorubicin 1ixabepilone 1fostamatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × C188-9 compound × Thoracic × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡